CLSA Board Goes to Washington to Meet with Members of Congress, Discuss Biomedical Innovation
May 21, 2017
On May 3, 19 members of CLSA’s board of directors spent a full day on Capitol Hill meeting with more than two dozen key members of Congress on issues of importance to California’s life sciences innovation ecosystem.
The CLSA board met with a number of legislators, including: House Majority Leader Kevin McCarthy (R-Bakersfield), Reps. Judy Chu (D-Los Angeles), Anna G. Eshoo (D-Silicon Valley), Doris Matsui (D-Sacramento), Raul Ruiz, MD (D-Palm Desert), Jackie Speier (D-San Mateo/South San Francisco), Eric Swalwell (D-East Bay), David Valadao (R-Hanford), Mimi Walters (R-Laguna Nigel), and with the senior policy advisor to Energy & Commerce Health Subcommittee Chair Michael Burgess, MD (R-Texas). In addition, we participated in a roundtable discussion with members of the New Democrat Coalition, including: Reps. Ami Bera, MD (D-Elk Grove), Julia Brownley (D-Thousand Oaks), Tony Cárdenas (D-Los Angeles), Susan Davis (D-San Diego), Scott Peters (D-San Diego), and Norma Torres (D-Pomona), as well as Kathleen Rice (D-N.Y.), and Darren Soto (D-Florida).
We capped off the day with a roundtable discussion hosted by Rep. Eric Swalwell (D-East Bay), including all five of our delegation’s new members: Reps. Nanette Diaz Barragan (D-Carson), Salud Carbajal (D-Santa Barbara), Lou Correa (D-Santa Ana), Ro Khanna (D-Sunnyvale/Silicon Valley) and Jimmy Panetta (D-Monterey).
CLSA’s board members discussed issues including: the importance of a patent system that preserves the ability for biomedical innovators to enforce their patents; our support for predictable and sustained NIH funding for basic research; the importance of a transparent and predictable FDA regulatory environment, including swift reauthorization of the FDA user fee programs; the need for a full repeal of the medical device tax; the need for a timely repeal of the Independent Payment Advisory Board (IPAB); and how public and private insurers can better value medical innovation through coverage and payment policies.
Questions? Please contact Jenny Carey, CLSA’s Vice President of Federal Government Relations and Alliance Development (firstname.lastname@example.org).